Replies to post #244745 on Biotech Values

[DewDiligence]

ICVX—(+24%)—reports_interim_phase-1_data_for bivalent RSV/hMPV vaccine:

https://www.globenewswire.com/news-release/2023/05/22/2673842/0/en/Icosavax-Announces-Positive-Topline-Interim-Phase-1-Results-for-Bivalent-VLP-Vaccine-Candidate-IVX-A12-Against-RSV-and-hMPV-in-Older-Adults.html

RSV and hMPV are similar viruses that cause similar respiratory symptoms. ENTA has a program for a dual RSV/hMPV (non-fusion) inhibitor in preclinical development (see slides 18-20 at https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4 ).

p.s. ICVX tried and failed to develop a COVID vaccine (#msg-168333026, #msg-169536055).